Dendritic Cell-Based Immunotherapy Combined With Second-Line Chemotherapy in Platinum-Sensitive Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Gynecologic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial
Gynecol. Oncol 2021 Sep 01;162(3)652-660, D Cibula, L Rob, P Mallmann, P Knapp, J Klat, J Chovanec, L Minar, B Melichar, A Hein, D Kieszko, M Pluta, J Spacek, P Bartos, P Wimberger, R Madry, J Markowska, J Streb, P Valha, HIB Hassan, L Pecen, L Galluzzi, J Fucikova, T Hrnciarova, M Hraska, J Bartunkova, R SpisekFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.